|
| Complications | ATG-F | Thymoglobulin | |
| |
|
| Adverse effect of antilymphocyte globulin perfusion, (%) | 4 (27) | 8 (53) | 0.14 |
|
| Graft failure, (%) | 1 (7) | 1 (7) | 1.00 |
|
| Rejection, (%) | 2 (13) | 3 (20) | 1.00 |
|
| Relapse, (%) | 5 (33) | 7 (47) | 0.46 |
|
| Cumulative incidence of relapse at 3 years (%) | 33.3 (16.3–68.2) | 40 (21.5–74.3) | 0.55 |
|
| CMV reactivation, (%) | 11 (73) | 10 (67) | 0.69 |
|
| Severe infection after aplasia, patients (%) | 9 (60) | 7 (47) | 0.46 |
|
| Respiratory infections, | 2 RSV
1 Staph. aureus
pneumonia | 2 H1N1 influenza
2 bacterial pneumonia
1 invasive lung
aspergillosis | |
|
| Bacteremia, | 2 Staphylococcus
1 Kytococcus schroeteri | 1 multiple
(E. coli, Pseudomonas sp., Listeria monocytogenes) | |
|
| Other infections, | 3 BK-virus cystitis
1 Microsporidiosis
3 E. coli urinary
1 HHV-6 encephalitis
2 genital HSV-1 | 1 gastroenteritis
1 acute middle otitis
1 generalized aspergillosis
1 large spectrum beta-lactamase
enterobacteria urinary | |
|
| Acute GvHD grade I, (%) | 2 (13) | 2 (13) | 1.00 |
|
| Acute GvHD grades II–IV, (%) | 6 (40) | 3 (20) | 0.23 |
|
| Cumulative incidence of aGvHD grades I–IV at day 100 (%) | 53.3 (33.2–85.6) | 26.7 (11.5–61.7) | 0.23 |
|
| Chronic limited GvHD, (%) | 0 | 1 (7) | 1.00 |
|
| Chronic extensive GvHD, (%) | 4 (27) | 3 (20) | 0.67 |
|
| Cumulative incidence of cGvHD at 3 years (%) | 13.3 (3.7–48.5) | 20.0 (7.3–55.0) | 0.87 |
|
| Death, (%) | 8 (53) | 8 (53) | 1.00 |
|
| TRM, cumulative incidence at 3 years (%) | 33.3 (16.3–68.2) | 20 (7.3–55) | 0.67 |
|
| OS, cumulative incidence at 3 years (%) | 46.7 (20.7–72.7) | 45.7 (19.7–71.7) | 0.97 |
|
| DFS, cumulative incidence at 3 years (%) | 33.7 (8.9–58.1) | 40.0 (14.8–65.2) | 0.86 |
|
